Commitments and Contingencies Operating Leases The Company leases a manufacturing facility located in Winnipeg, Manitoba Canada, which consists of an approximately 31,400 square foot manufacturing, laboratory, warehouse and office facility, under a five year renewable lease through September 2020 with a right to renew the lease for one subsequent five -year term. The minimum monthly rent under this lease is approximately $25,000 per month, plus additional rent and applicable taxes. Rent expense under this lease was $86,000 for the period beginning on the Acquisition Date through December31, 2016 . The Company leased its corporate headquarters in Cambridge, Massachusetts under an operating lease that was scheduled to expire on April 30, 2018. On October 14, 2016, the Company and the landlord mutually agreed to terminate the lease and voluntarily surrender the premises. The Company recorded $565,000 , $494,000 and $416,000 in rent expense for the years ended December31, 2016 , 2015 and 2014 , respectively, for this lease. The minimum aggregate future lease commitment at December31, 2016 is as follows (in thousands): 2017 $ 324 2018 296 2019 296 2020 222 $ 1,138 License Agreements The Company is a party to or assignee of license agreements that may require it to make future payments relating to license fees, sublicense fees, milestone fees, and royalties on future sales of licensed products. The following outlines the license agreements the Company believes it will owe payments under if its product candidates reach certain milestones and begin to generate revenue. The Schepens Eye Research Institute, Inc. / The Massachusetts Eye and Ear Infirmary In July 2010, the Company entered into a license agreement with The Schepens Eye Research Institute, Inc. (Schepens), pursuant to which Schepens granted the Company an exclusive royalty-bearing license, with the right to grant sublicenses, to certain intellectual property rights for the development of IL-1blocker for ophthalmic indications. The Company is obligated to